Research

Hormonal

Synthetic agonists of the NR4A subgroup (e.g., 6-mercaptopurine, cytosporone B) can modulate receptor activity to potentially treat metabolic and cardiovascular diseases, although their clinical utility is currently limited by poor potency and lack of endogenous ligand specificity.

Researchers have identified synthetic drugs that can activate NR4A receptors, which might help treat obesity and diabetes in the future. However, these drugs are currently just research tools with weak effects and unknown long-term safety. For now, the best way to activate these beneficial receptors is through natural stimuli like exercise and healthy eating, which the body is evolved to handle.

LimitedQualifiesLOW confidence
The preliminary studies reviewed in this manuscript suggest that therapeutic exploitation of the NR4A subgroup may show utility against dyslipidemia, obesity, diabetes, and cardiovascular disease... Several small molecule agonists have recently been identified.
Michael A. Pearen et al. · Molecular Endocrinology · 2010

Why this rating

Based on early-stage synthetic compound studies in vitro and animal models; no human efficacy data.

Source

Minireview: Nuclear Hormone Receptor 4A Signaling: Implications for Metabolic Disease

Michael A. Pearen et al. · Molecular Endocrinology · 2010

DOI 10.1210/me.2010-0015

narrative_reviewCited 310×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →